MedTrace Logo

Dopamine Responsivity in Gamblers

NCT02772978 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

This study deals with how people decide between rewards of different value. The investigators want to understand how the brain's dopamine system impacts this kind of decision making. The investigators will use a medication, tolcapone, which can temporarily affect the dopamine system.

Conditions

  • Pathological Gambling

Interventions

DRUG

Tolcapone

Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors

DRUG

Placebo

A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients

Sponsors & Collaborators

Principal Investigators

  • Andrew Kayser, MD, PhD · University of California at San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-09-30
Completion
2015-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772978 on ClinicalTrials.gov